MedTrace Logo

The Off Label Use of Glycopyrrolate in the Adults Intensive Care Unit.

NCT04554589 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-09-23

No results posted yet for this study

Summary

Tracheostomized patients in the ICU can have excessive tracheal secretions due to various causes as hyperactive airway, irritation of the mucus producing cells and inhibition of the ciliary functions. Excessive secretions will necessitate frequent suctions which carries the risk of tracheostomy tube obstruction if not managed properly. Excessive tracheal secretions may prolong the ICU stay, increase the nurses workload and increase patients morbidity and mortality.

This clinical trial hypothesizes that the use of glycopyrrolate may decrease the tracheal secretions and hence avoid such complications.

Conditions

  • Effect of Drugs

Interventions

DRUG

Glycopyrrolate 0.2 MG

injections

DRUG

normal saline

normal saline

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Mohammed Abosamak, MD · health care provider

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-14
Primary Completion
2021-02-10
Completion
2021-04-10
FDA Drug
Yes

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04554589 on ClinicalTrials.gov